Search Results 361-370 of 16343 for immunothérapie Bylaska

  1. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined Regimen Of Mosunetuzumab And Venetoclax In Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

    ... immunotherapy not explicitly defined by the protocol is to be discussed with the medical monitor to determine eligibility * Received a live, attenuated ...

  2. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  3. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  4. Department of Immunology - Mayo Clinic Research

    Many researchers in the department are engaged in cancer immunology, cancer immunotherapy and cancer biology research. Many of these researchers belong to ...

  5. B-cell lymphoma - Doctors and departments - Mayo Clinic

    Muhamad Alhaj Moustafa, M.D., M.S.. Oncologist; Hematologist. Jacksonville, FL. Areas of focus: Chemotherapy, Immunotherapy, Bone marrow biopsy and aspiration ...

  6. Follicular Lymphoma Clinical Trials

    ... immunotherapy, or chemoimmunotherapy. Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular ...

  7. Study of BLU-667 in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors - Mayo Clinic

    Any immunotherapy or other antibody therapy within 28 days prior to the first dose of study drug (immune related toxicities must have resolved to < Grade 2 ...

  8. A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma - Mayo Clinic

    Participation eligibility · Patients must not have received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone ...

  9. Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

    Participation eligibility · Therapeutic antibodies, such as bevacizumab · Small molecule kinase inhibitors, such as pazopanib · Vaccines and immunotherapy All of ...

  10. Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer - Mayo Clinic

    Participation eligibility · Chemotherapy ≤ 28 days prior to registration · Mitomycin C/nitrosoureas ≤ 42 days prior to registration · Immunotherapy ≤ 28 days ...